


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound comprising the formula:



or a pharmacologically acceptable addition salt thereof,

wherein **R₁** and **R₂** are independently selected from the group consisting of:

a) hydrogen;


b) alkyl, alkenyl of not less than 3 carbons, or alkynyl of not less than 3 carbons; wherein said alkyl, alkenyl, or alkynyl is either unsubstituted or substituted with one or more substituents selected from the group consisting of hydroxy, alkoxy, amino, alkylamino, dialkylamino, heterocyclyl, acylamino, alkylsulfonylamino, and heterocyclylcarbonylamino; and

c) aryl or aryl substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, amino, nitro, carboxy, carbalkoxy, cyano, alkylamino,

dialkylamino, halo, hydroxy, hydroxyalkyl, mercaptyl, alkylmercaptyl, trihaloalkyl, carboxyalkyl, sulfoxy, and carbamoyl;

R_3 is selected from the group consisting of:


(a) a bicyclic, tricyclic or pentacyclic group selected from the group consisting of:



wherein the bicyclic or tricyclic group is either unsubstituted or substituted with one or more substituents selected from the group consisting of:

oxo, R_5 -alkylsulfonylamino, and R_5 -alkylthio; and

(b) the tricyclic group:



wherein the tricyclic group is substituted with one or more substituents selected from the group consisting of:


(a) alkyl, alkenyl, and alkynyl; wherein each alkyl, alkenyl, or alkynyl group is either unsubstituted or substituted with one or more substituents selected from the group consisting of (amino)(R₅)acylhydrazinylcarbonyl, (amino)(R₅)acyloxycarboxy, (hydroxy)(carboalkoxy)alkylcarbamoyl, acyloxy, aldehydo, alkenylsulfonylamino, alkoxy, alkoxycarbonyl, alkylaminoalkylamino, alkylphosphono, alkylsulfonylamino, carbamoyl, R₅, R₅-alkoxy, cyano, cyanoalkylcarbamoyl, cycloalkylamino, dialkylamino, dialkylaminoalkylamino, dialkylphosphono, haloalkylsulfonylamino, (heterocyclalkyl)amino, heterocyclcarbamoyl, hydroxy, hydroxyalkylsulfonylamino, oximino, substituted aralkylamino, substituted arylcarboxyalkoxycarbonyl, substituted heteroarylsulfonylamino, substituted heterocycl, thiocarbamoyl, and trifluoromethyl; and

(b) (alkoxycarbonyl)aralkylcarbamoyl, aldehydo, alkenoxy, alkenylsulfonylamino, alkoxy, alkoxycarbonyl, alkylcarbamoyl, alkoxycarbonylamino, alkylsulfonylamino, alkylsulfonyloxy, amino, aminoalkylaralkylcarbamoyl, aminoalkylcarbamoyl, aminoalkylheterocyclalkylcarbamoyl, aminocycloalkylalkylcycloalkylcarbamoyl, aminocycloalkylcarbamoyl, aralkoxycarbonylamino, arylheterocycl, aryloxy, arylsulfonylamino, arylsulfonyloxy, carbamoyl, oxo, -R₅, R₅-alkoxy, R₅-alkyl(alkyl)amino, R₅-alkylalkylcarbamoyl,

R_5 -alkylcarbamoyl, R_5 -alkylsulfonyl, R_5 -alkylsulfonylamino, R_5 -alkylthio, R_5 -heterocyclylcarbonyl, cyano, cycloalkylamino, dialkylaminoalkylcarbamoyl, halogen, heterocyclyl, (heterocyclylalkyl)amino, oximino, substituted aralkylamino, substituted heterocyclyl, substituted heterocyclylsulfonylamino, ~~(sulfoxyacyl)amino~~, and thiocarbamoyl;

R_4 is selected from the group consisting of hydrogen, C_{1-4} -alkyl, C_{1-4} -alkyl- CO_2H , and phenyl, wherein the C_{1-4} -alkyl, C_{1-4} -alkyl- CO_2H , and phenyl groups are either unsubstituted or substituted with one to three substituents selected from the group consisting of halogen, -OH, -OMe, - NH_2 , NO_2 , benzyl, and benzyl substituted with one to three substituents selected from the group consisting of halogen, -OH, -OMe, - NH_2 , and - NO_2 ;

R_5 is selected from the group consisting of - CH_2COOH , - $C(CF_3)_2OH$, - $CONHNHSO_2CF_3$, - $CONHOR_4$, - $CONHSO_2R_4$, - $CONHSO_2NHR_4$, - $C(OH)R_4PO_3H_2$, - $NHCOCF_3$, - $NHCONHSO_2R_4$, - $NHPO_3H_2$, - $NHSO_2R_4$, - $NHSO_2NHCOR_4$, - OPO_3H_2 , - OSO_3H , - $PO(OH)R_4$, - PO_3H_2 , - SO_3H , - SO_2NHR_4 , ~~- OSO_2NHCOR_4~~ , ~~- $OSO_2NHCONHCO_2R_4$~~ , and the following:



X₁ and **X₂** are independently selected from the group consisting of O and S;

Z is selected from the group consisting of a single bond, -O-, -(CH₂)₁₋₃-, -O(CH₂)₁₋₂-, -CH₂OCH₂-, -(CH₂)₁₋₂O-, -CH=CHCH₂-, -CH=CH-, and -CH₂CH=CH-; and

R₆ is selected from the group consisting of hydrogen, alkyl, acyl, alkylsulfonyl, aralkyl, substituted aralkyl, substituted alkyl, and heterocyclyl.

2. (Original) The compound of claim 1, wherein the compound is in a form selected from the group consisting of an achiral compound, a racemate, an optically active compound, a pure diastereomer, a mixture of diastereomers, and a pharmacologically acceptable addition salt.

3. (Original) The compound of claim 1, wherein **R₁** and **R₂** are each alkyl groups.


4. (Original) The compound of claim 1, wherein **R₁** and **R₂** are each n-propyl.

5. (Previously presented) The compound of claim 1, wherein **R₁** is n-propyl and **R₆** is selected from the group consisting of an unsubstituted aralkyl; aralkyl substituted with -OH, -OMe, or -halogen; methyl; and 3-hydroxypropyl.

6. (Original) The compound of claim 4, wherein **Z** is a single bond.

7 – 10. (Canceled).

11. (Previously presented) The compound of claim 6, wherein R_3 is



- 12 – 38. (Canceled).

39. (Original) A medicament composition comprising a compound of claim 1 together with a suitable excipient.

40. (Canceled).

41. (Currently amended) A method of treating a subject suffering from a disease or condition selected from the group consisting of respiratory disorders, diseases for which diuretic treatment is indicated, depression, traumatic brain damage, respiratory depression, neonatal brain trauma, cirrhotic ascites, neonatal apnea, renal failure, diabetes, and asthma, the method comprising administering to the subject an effective adenosine antagonizing amount of a compound of claim 1.

42. (Currently amended) A method of treating a subject suffering from a disease, ~~wherein the condition is congestive heart failure,~~ the method comprising administering to the subject an effective adenosine antagonizing amount of a compound of claim 1.

43. (Canceled).